Bristol-Myers Squibb Co
-
Innate Pharma (Euronext Paris: FR0010331421 - IPH): First Patient Treated in the EffiKIR Trial (Mon, Dec 17)
-
The Medicines Company and Bristol-Myers Squibb Agree to Global Alliance for Recothrom(R) (Wed, Dec 12)
-
Bristol-Myers Squibb Foundation Awards Mental Health Grants of Nearly $3 Million to Support Returning Veterans (Tue, Dec 11)
-
Elotuzumab Progression-Free Survival Data from Phase 2 Study of Patients with Previously-Treated Multiple Myeloma Presented at 54th American Society of Hematology (ASH) Annual Meeting (Sun, Dec 9)
-
ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended Treatment (Sat, Dec 8)
-
Bristol-Myers Squibb Announces Dividend Increase (Tue, Dec 4)
-
ELIQUIS®(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation (Tue, Nov 20)
